Audentes Therapeutics, Inc. (BOLD) Stock: Worthy of a Trade, Wary of an Investment

The stock of Audentes Therapeutics, Inc. (NASDAQ:BOLD) has been Reiterated to Buy by H.C. Wainwright in its latest research note that was published on April 26. BOLD has given a price target of $48 by H.C. Wainwright, with other Wall Street analysts also giving their reports regarding the stock. Citigroup analysts have downgraded their rating of BOLD stock from Neutral to Sell in a separate flash note to investors on April 26. Analysts at Chardan Capital Markets issued an upgrade fromNeutral to Buy for the stock, in a research note that dated back to February 25.

Audentes’s stock is covered by 13 analysts, with 3 of them rating the stock as Buy. It has been deemed to have strong buy by 7 of the analysts, 2 of them have rated it as a Hold while 1 of them rated it as sell. The situation was different a month ago when the stock was rated as a Buy by only 4 analysts. 7 of them rated it as strong buy with 2 of them recommended investors to Hold on to the stock. Meanwhile, none analyst(s) rated it as a sell. The above data shows that BOLD has an average analyst rating of 2.15.

Audentes Therapeutics, Inc., which has current market capitalization of above $1 Billion, published its last quarter earnings on June 30, 2019. During the first quarter of the year, Audentes also recorded $-1.13 earnings per share (EPS) which is $0.24 above the $-0.89 estimated by Thomson Reuter’s analyst, leading to a surprise factor of -27.61%.

BOLD declined by $-0.49 during the normal trading session on Monday and reaching a high of $34.98 during the day while it closed the day at $33.65. The Audentes stock had a low trading volume of 0.33 million shares on that day, which is low compared to the average daily volume of 489.50M shares. BOLD has also lost 5.74% of its value over the past 7 days. However, the stock has declined by 8.34% in the 3 months of the year. Over the past six months meanwhile, it has gained 43.25% while it has added 57.83% year-on date. Let us now take a look at the stock’s potential support and resistance levels. The publicly traded company was seen to have slipped by -18.42% from its 3 months high price. However, taking another look at BOLD will indicate that it is trading +0.99% away from its 90-day low. Looking at the bigger picture, the Audentes Therapeutics, Inc. stock has dropped by -19.21% from its 52-week high while it has surged by +87.47% from its 52-week low price.

On June 24, 2019 LANGE LOUIS G, Director sold 21000 shares of the company. The average price for that transaction was $37.79 per share, which meant that LANGE LOUIS G earned $793590 selling the stocks. The sale was made public, with the document of the transaction filed with the SEC. Another insider trading occurred, with Senior VP & Chief Med Officer, PRASAD SUYASH selling 10000 shares of this stock on May 13, 2019. The average selling price for the stock was $36.98 per share, with the sold stock accruing $369800. Following this transaction, the Senior VP & Chief Med Officer PRASAD SUYASH now holds 28236 shares of the company, which is worth around $1001531.

Looking at the stock’s Technical analysis information over the past 50 days shows that its Raw Stochastic average stood at 4.16%. This figure is worse than the company’s 20-day Raw Stochastic average which currently stands at 4.6%. Over the past 20 days, Audentes’s Stochastic %K stood at 17.61% while its Stochastic %D was revealed to be 24.46%.